

August 3, 2017
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice Concerning Non-operating Income

SymBio Pharmaceuticals Limited (“the Company”) announces accrued non-operating income for the second quarter of the fiscal year ended December 31, 2017 (from April 1, 2017 to June 30, 2017) as follows.

1. Details of Non-operating Income

The Company recorded a foreign exchange gain of 27,930 thousand yen under non-operating income for the second quarter of the fiscal year ended December 31, 2017 (from April 1, 2017 to June 30, 2017) due to recent fluctuations in foreign exchange rates. In addition, with a foreign exchange loss of 55,197 thousand yen for the three months ended March 31, 2017, a total foreign exchange loss of 27,266 thousand yen was recorded in the Statements of Operations for the second quarter of the fiscal year ended December 31, 2017.

2. Future Outlook

Based on its assumption concerning operational trends for this fiscal year, the Company determined that this non-operating income would have no significant impact on the results of operations for the year with no modification to the financial forecast required. The Company will make a prompt announcement should any modification to the financial forecast be necessary.

[Contact]

Investor Relations
Tel: +81(0)3 5472 1125